Business Wire

Moody’s Analytics Launches Accelerator to Fast Track Innovation and Explore New Markets

Del

Moody’s Analytics is pleased to announce the launch of its Accelerator, formed to leverage emerging technologies to build the next generation of Moody’s Analytics solutions.

The Moody’s Analytics Accelerator team leverages a disciplined approach to early stage product development and forms strategic partnerships with leading financial technology companies to explore new business opportunities adjacent to the Moody’s Analytics core businesses.

“The Accelerator framework allows our team to be dedicated to bringing innovations to customers,” said Keith Berry, Executive Director of the Moody’s Analytics Accelerator. “Our vision is to help Moody’s Analytics customers navigate the evolving marketplace with confidence by using the technologies of tomorrow to solve the challenges of today.”

The Accelerator searches for new ways to combine Moody’s Analytics extensive data resources with the technologies that are revolutionizing business today. The Accelerator team is currently focusing resources on two initial areas of product development:

  • Automating customer workflows using technologies such as machine learning and artificial intelligence.
  • Growing the Moody’s Analytics Commercial Real Estate data and analytics offering as the company expands its solutions set across all CRE workflows.

“We created the Accelerator to ensure Moody’s Analytics continues to lead the industry in data and analytics, helping customers make better, faster decisions,” said Mark Almeida, President of Moody’s Analytics. “The Accelerator is an integral part of our business and I look forward to its work advancing the evolution of our company.”

Click here to learn more about the Moody’s Analytics Accelerator.

About Moody’s Analytics

Moody’s Analytics provides financial intelligence and analytical tools to help business leaders make better, faster decisions. Our deep risk expertise, expansive information resources, and innovative application of technology help our clients confidently navigate an evolving marketplace. We are known for our industry-leading and award-winning solutions, made up of research, data, software, and professional services, assembled to deliver a seamless customer experience. We create confidence in thousands of organizations worldwide, with our commitment to excellence, open mindset approach, and focus on meeting customer needs. For more information about Moody’s Analytics, visit www.moodysanalytics.com.

Moody's Analytics is a subsidiary of Moody's Corporation (NYSE: MCO). MCO reported revenue of $4.2 billion in 2017, employs approximately 12,600 people worldwide and maintains a presence in 42 countries.

Contact information

KATERINA SOUMILOVA
Assistant Vice-President
Moody’s Analytics Communications
001.212.553.1177
katerina.soumilova@moodys.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

New Phase 3 data demonstrate superiority of TREMFYA®▼ (guselkumab) vs Cosentyx® (secukinumab) in delivering PASI 90 responses in the treatment of moderate to severe plaque psoriasis at week 4817.12.2018 12:56Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the ECLIPSE study demonstrating that TREMFYA® (guselkumab) was superior to Cosentyx® (secukinumab)* in treating adults with moderate to severe plaque psoriasis for the primary endpoint assessed at week 48. Data from the multicentre, randomised, double-blind head-to-head Phase 3 study demonstrated that 84.5 percent of patients treated with guselkumab achieved at least 90 percent improvement in their baseline Psoriasis Area Severity Index (PASI) score at week 48, compared with 70.0 percent of patients treated with secukinumab (p<0.001).1 These data, presented at the 3rd Inflammatory Skin Disease Summit (ISDS) in Vienna, 12–15 December, mark the first-ever results from a head-to-head study comparing an interleukin (IL)-23-targeted biologic therapy (guselkumab) with an IL-17 inhibitor (secukinumab). ECLIPSE is Janssen’s fourth Phase 3 study for guselkumab in plaque psoriasis2-4 and is part of a comprehen

Celgene Corporation Announces Celgene Cancer Care Links™ Program Grant Recipients17.12.2018 12:30Pressemelding

Celgene Corporation (NASDAQ:CELG) today announced ten programs selected for funding under its Celgene Cancer Care Links™ program, an initiative designed to support cancer healthcare capacity building in resource-constrained countries around the world. The programs selected are expected to support established institutions partnering with in-country medical centers that provide essential cancer care services including awareness and education, prevention, diagnosis and care. The Celgene Cancer Care Links program is an initiative of Celgene Global Health, which focuses on healthcare challenges facing patients in developing parts of the world. “Celgene Cancer Care Links is another program we have created to make a meaningful impact for patients and healthcare systems around the world,” said Mark J. Alles, Chairman and Chief Executive Officer of Celgene. “We are excited to announce the first round of grants through this initiative and wish these world-renowned organizations and institutions

Ras Al Khaimah Marks New Year’s Eve with Amazing Fireworks and New Guinness World Record Bid17.12.2018 11:14Pressemelding

This New Year’s Eve, Ras Al Khaimah is the place to be as the Emirate readies to host the most spectacular celebration with a 12-minute fireworks display - the bid for a new Guinness World Record display - and an array of family-oriented activities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181217005309/en/ Marjan, Ras Al Khaimah’s master-developer of freehold projects, will manage the show to mark 2019 with a glittering array of activities that will entertain all at its flagship development, Al Marjan Island. With three additional viewing areas around Al Marjan Island, New Year’s Eve in Ras Al Khaimah has fun and thrills in store for local and international visitors. Abdulla Al Abdouli, Managing Director & CEO of Marjan, said: “This year, we are offering exciting family activities that will delight all in the run-up to the amazing fireworks display that aims to set a new Guinness World Record. The event will position t

Mobidiag Announces Joint Venture with Autobio Diagnostics and €10m Equity Investment17.12.2018 09:52Pressemelding

Mobidiag Ltd., a commercial stage molecular diagnostics company addressing the spread of antimicrobial resistance, today announces that it has entered into a joint venture (‘JV’) agreement with Autobio Diagnostics (‘Autobio’), one of the leading clinical diagnostics companies in China, to commercialise the Novodiag® platform in China. In addition, Mobidiag announces that it has secured a separate €10m equity investment from Autobio. Lynx Financial (HK) Ltd, served as the exclusive financial advisor to Mobidiag in this transaction. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181217005272/en/ Mobidiag and Autobio will jointly invest €12.3m to establish a joint venture company in China. Autobio will invest €8m in cash to hold 65%, and Mobidiag will invest €4.3m to hold 35%. Mobidiag will grant to the JV an exclusive license for human infectious disease assays (except for sepsis) for China. Initial activities of the JV will i

Prima Solutions and Effisoft Announce Their Merger to Bolster Global Leadership in Providing Insurance Solutions17.12.2018 09:00Pressemelding

As part of their continuing growth strategies, Prima Solutions and Effisoft announce their merger to create a global InsureTech company. This merger between Effisoft, the leading vendor of reinsurance and regulatory software solutions for insurance and reinsurance companies across the globe, and Prima Solutions, one of Europe’s leading software provider for Life, Health, and P&C insurance companies, will produce one of the largest and most comprehensive players in Europe, North America, and the Asia-Pacific region with cloud-based solutions covering all areas of the insurance market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181217005249/en/ This merger, concluded on December 13, will enable both groups to accelerate their development in the P&C, health and personal protection insurance markets. This merger is part of an ambitious and coherent growth strategy: it completes Prima Solutions' and Effisoft's existing produc

Algorand Appoints Pablo Azar as Chief Economist17.12.2018 09:00Pressemelding

Algorand, a foundational blockchain and cryptocurrency company, announced today that it has named Pablo Azar as Chief Economist. Given Algorand's focus on creating sustainable value in a decentralized economy, Mr. Azar will be responsible for guiding Algorand’s economic policies. On the heels of announcing Steve Kokinos and W. Sean Ford as CEO and COO, respectively, Mr. Azar’s appointment as Chief Economist is another advancement for Algorand as it continues to develop its executive team. With a double Ph.D. from MIT, Mr. Azar will bring his unique expertise regarding the application of computer science and cryptography toward the creation of better market mechanisms. Further, he will be responsible for expanding the visibility of Algorand’s economic policy and enhancing the tools necessary for developers to build on the Algorand platform. “As momentum around tokenization increases, so does the need for sound economic management,” said Steve Kokinos, CEO at Algorand. “With his deep bac